Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 vs Salmeterol/Fluticasone in Adolescents With Asthma
NCT05776927Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 9
01
Overview
A Phase 3 trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma, sponsored by Novartis. Started Aug 2026; status: recruiting.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05776927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776927.